Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Piboserod

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Piboserod
Clinical data
Trade namesSerlipet
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • Clinical phase II
Identifiers
  • N-((1-Butyl-4-piperidyl)-methyl)-3,4-dihydro-2H-(1,3)oxazino(3,2-a)indole-10-carboxamide
CAS Number
PubChemCID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC22H31N3O2
Molar mass369.509 g·mol−1
3D model (JSmol)
  • CCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1
  • InChI=1S/C22H31N3O2/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26) ☒N
  • Key:KVCSJPATKXABRQ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Piboserod is a selective5-HT4 receptorantagonist which was marketed and manufactured byGlaxoSmithKline (GSK) under the trade nameSerlipet for the management ofatrial fibrillation andirritable bowel syndrome. In 2007 the Norwegian company Bio-Medisinsk Innovasjon AS (BMI)[1] completed aclinical phase II study to investigate the effect of piboserod in patients with chronicheart failure.

Mechanism of action

[edit]

In 2002 a research group at theUniversity of Oslo discovered that muscles from theventricle of failing hearts have increased responsiveness toserotonin.[2] They later demonstrated that the effect was due to anexpression of functional 5-HT4 receptors in the failing muscle. On the basis of these findings, and in analogy with the success ofbetablockers in heart failure, the group made the hypothesis that 5-HT4 receptor antagonists could be useful to treat heart failure. Their hypothesis was tested inanimal models of heart failure with positive results.[3]

References

[edit]
  1. ^Company web-page
  2. ^Brattelid T, Qvigstad E, Lynham JA, Molenaar P, Aass H, Geiran O, et al. (September 2004). "Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure".Naunyn-Schmiedeberg's Archives of Pharmacology.370 (3):157–66.doi:10.1007/s00210-004-0963-0.PMID 15365689.S2CID 12306762.
  3. ^Birkeland JA, Sjaastad I, Brattelid T, Qvigstad E, Moberg ER, Krobert KA, et al. (January 2007)."Effects of treatment with a 5-HT4 receptor antagonist in heart failure".British Journal of Pharmacology.150 (2):143–52.doi:10.1038/sj.bjp.0706966.PMC 2042907.PMID 17160012.
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Subsidiaries
Current
Former
Predecessors,
acquisitions
Products
Current
Pharma
Vaccines
Former
People
Board of
Directors
Other
Litigation
Other
Retrieved from "https://en.wikipedia.org/w/index.php?title=Piboserod&oldid=1190969785"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp